Hormonal treatment of thyroid cancer

Free thyroid hormones and a third-generation TSH assay in the detection of hyperthyroidism during long-term thyroxine treatment in thyroid carcinoma patients

We evaluated the value of serum-free thyroid hormone and thyrotropin (TSH) concentrations in the detection of peripheral hyperthyroidism during thyroxine suppression therapy. A total of 57 patients on a stable thyroxine dose and 70 controls participated in the study. Serum-free thyroxine (FT4), free triiodothyronine (FT3) and TSH were measured by immunoassays based on time-resolved fluorescence (Delfia). The assay for TSH was a modification of a third generation Delfia hTSH Ultra method. The patients were classified into euthyroid and hyperthyroid subgroups based on clinical signs and symptoms (Wayne index). Systolic time intervals (STI) were measured. The Wayne indices were higher among patients than controls (p < 0.0001). The STI results were similar in patients and controls. Only FT4 had the discriminatory power for classifying euthyroid and hyperthyroid patients according to discriminant analyses. The diagnostic value of FT4 was further assessed by calculating the area under the relative operating characteristic (ROC) curve. The area was 0.707 (SE 0.0918), which was significantly different from an area of 0.5, i.e. the area of a test of no value (p = 0.032). In conclusion, a high serum FT4 concentration indicates hyperthyroidism during long-term thyroxine treatment among thyroid carcinoma patients. Although the degree of TSH suppression can now be exactly monitored with new third generation TSH assays, hyperthyroidism cannot be defined using TSH concentration in thyroid carcinoma patients. Therefore, additional serum FT4 concentration assays are needed in the assessment of hyperthyroidism associated with TSH suppression therapy in thyroid carcinoma patients.

Thyroid cancer

Management of thyroid cancer varies somewhat between communities and institutions depending on tumor type and individual treatment philosophy. The differentiated thyroid cancers have a significantly better outlook than the medullary and anaplastic. This article provides an overview of the literature that describes pathogenesis, diagnosis, and treatment currently recommended for these thyroid cancers.

Role of thyroid stimulating hormone suppression in the management of thyroid cancer

Well-differentiated thyroid cancers (papillary, follicular, and some Hurthle cell tumors) contain membrane receptors for TSH. Responsiveness of these tumors to TSH stimuli is documented by increased radioactive iodine uptake, secretion of thyroglobulin, increase in thyroid size, and potential progression to an anaplastic type. Although TSH suppression has a variable effect on the growth of existing tumors and the incidence of recurrent disease, there is a sound rationale for long-term TSH suppression in all patients with differentiated tumors of the thyroid. The ultrasensitive TSH test permits ready monitoring of the adequacy of thyroxine dosage. The cost is minimal (approximately $.10/day) and the risks are negligible if one assumes the avoidance of hyperthyroxinemia.

Thyroid cancer

There have been important recent advances in our understanding of the biologic nature of thyroid cancer and in the early diagnosis of the disease. Despite these advances, there is still considerable controversy over the management of thyroid cancer, including the extent of surgery, the indications for the use of iodine-131, the effectiveness of thyroid-stimulating hormone suppression, and the prediction of outcome. In this review, the current status of the diagnosis and management of the various types of thyroid cancer are carefully reviewed and extensively documented.

Factors influencing the growth of normal and neoplastic thyroid tissue

TSH activates the adenylate cyclase and the phosphoinositide turnover-protein kinase C-calcium systems in thyroid cells and appears to have an important but variable role in controlling the growth of both normal and neoplastic thyroid tissues. Species differences, experimental conditions, and tissue or tumor cell heterogeneity may account for this variability. Although TSH seems to be an important physiologic growth factor, it is neither the exclusive growth factor for the thyroid gland nor absolutely necessary for the effect of other thyroid growth factors. TSH may work in concert with other growth factors such as EGF. Some growth factors influence thyroid growth through TSH, whereas others do not.

Thyroid carcinoma following treatment for acute lymphoblastic leukemia

A 2 1/2-year-old girl with acute lymphoblastic leukemia received chemotherapy and prophylactic cranial irradiation. After six years of remission, including three years off therapy, metastatic thyroid carcinoma appeared in the cervical lymph nodes. The predisposing factors for the development of thyroid carcinoma as a second malignancy in this case are discussed. It is suggested that thyroid carcinoma should be added to the growing list of second malignancies in acute lymphoblastic leukemia and that careful thyroid examination be included in the follow-up of long-term survivors.

Is childhood thyroid cancer a lethal disease?

The clinical, pathological, surgical, postoperative findings and survivorship of 58 patients younger and 513 patients older than 21 years at the time of diagnosis with thyroid neoplasms are reported. The younger patients have a predominance of well differentiated carcinomas which are more likely to be follicular. The lesions tend to be more advanced at the time of diagnosis, are treated by more aggressive surgery in the younger patients and are associated with a much better prognosis. Lack of progression of well to poorly differentiated neoplasms and a greater sensitivity to and dependence upon TSH in young patients, are two factors which may contribute to the striking difference in the prognosis of well differentiated thyroid carcinoma related to age.